MITO16b Trial: Bevacizumab in Platinum-Sensitive Ovarian Cancer with Sandro Pignata
Mar 18, 2021•27 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Sandro Pignata to discuss the MITO16b trial. Dr. Pignata is president of the Multicenter Italian Trial in Ovarian cancer (MITO) group, member of the educational committee of ESMO, Past Chair of the European Network of Gynaecological Oncological Trial Groups (ENGOT), and member of the board of directors of the Gynecologic Cancer InterGroup (GCIG).
Highlights:
- The paper published on the Lancet demonstrate that bevacizumab given at recurrence is effective also in patients already treated with bevacizumab in first line.
- Exploratory analysis suggest that this effect is not present in BRCA mutated patients.
For the best experience, listen in Metacast app for iOS or Android